HeartBeat.bio

HeartBeat.bio is a TechBio company developing a next-generation platform for cardiac drug discovery based on its proprietary human heart organoids, called Cardioids. These 3D models replicate the architecture and function of human heart chambers, enabling scalable, high-throughput disease modeling and compound screening. The company has secured strategic collaborations with major pharmaceutical and technology partners, such as Boehringer Ingelheim and Molecular Devices, and raised €4.5 million in a Pre-Series A round to scale its platform. Its business model centers on providing a technology platform and research services to accelerate and de-risk drug development for heart failure, cardiomyopathies, and other cardiac conditions.

Proprietary platform for generating 3D human heart chamber organoids ('Cardioids') from induced pluripotent stem cells (iPSCs). The technology enables self-organization of key cardiac cell types into a beating, hollow structure. It is integrated with automation for high-throughput screening in 384-well format and AI-driven data analytics for phenotypic analysis.

HeartBeat.bio competes in the human-relevant drug discovery model space. Direct competitors include other companies developing 3D cardiac models (e.g., engineered heart tissues from companies like Novoheart or Ncardia) and broader organoid platform companies. Its differentiation lies in the self-organizing, chamber-like structure of its Cardioids and its integrated automation/AI platform designed for industrial-scale screening.